• Raymund R Razonable, Kelly M Pennington, Anne M Meehan, John W Wilson, Adam T Froemming, Courtney E Bennett, Ariela L Marshall, Abinash Virk, and Eva M Carmona.
• Division of Infectious Diseases, Mayo Clinic, Rochester, MN. Electronic address: Razonable.raymund@mayo.edu.
• Mayo Clin. Proc. 2020 Jul 1; 95 (7): 146714811467-1481.

AbstractThe novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19), which presents an unprecedented challenge to medical providers worldwide. Although most SARS-CoV-2-infected individuals manifest with a self-limited mild disease that resolves with supportive care in the outpatient setting, patients with moderate to severe COVID-19 will require a multidisciplinary collaborative management approach for optimal care in the hospital setting. Laboratory and radiologic studies provide critical information on disease severity, management options, and overall prognosis. Medical management is mostly supportive with antipyretics, hydration, oxygen supplementation, and other measures as dictated by clinical need. Among its medical complications is a characteristic proinflammatory cytokine storm often associated with end-organ dysfunction, including respiratory failure, liver and renal insufficiency, cardiac injury, and coagulopathy. Specific recommendations for the management of these medical complications are discussed. Despite the issuance of emergency use authorization for remdesivir, there are still no proven effective antiviral and immunomodulatory therapies, and their use in COVID-19 management should be guided by clinical trial protocols or treatment registries. The medical care of patients with COVID-19 extends beyond their hospitalization. Postdischarge follow-up and monitoring should be performed, preferably using telemedicine, until the patients have fully recovered from their illness and are released from home quarantine protocols.Copyright © 2020. Published by Elsevier Inc.

36 keywords...

hide…